At least 10 companies reduced their workforces during the third quarter, compared to at least 15 in the same period last year. All cash and operating loss figures in $M. (A) 12-month operating loss at June 30; (B) Six-month net loss at June 30



Staff cuts


Yrs cash pre-cut

Cash date

6-mo op loss ended 6/30


Evotec AG (Xetra:EVT)

Reduce by 120





Cuts from closure of Evotec India Pvt. Ltd. in Thane, India, as Evotec shifted its chemistry operations to its facility in Abingdon, U.K. Evotec cited a need to "operate closer to the principal R&D laboratories of our major customers." Evotec had 661 employees at June 30. It anticipates hiring due to growth at other sites. Cash includes €30.1M ($40.2M) raised in an August private placement.


Array BioPharma Inc. (NASDAQ:ARRY)

20% to ~200




$39.5 (A)

Cuts primarily from drug discovery. By year end, Array expects to make decisions regarding pivotal trial plans for its two clinical cancer programs: ARRY-520, a kinesin spindle protein (KSP; Eg5; TRIP5) inhibitor; and ARRY-614, an inhibitor of P38 mitogen-activated protein (MAP) kinase and tyrosine kinase receptor 2 (Tie2). The company expects to save over $10M annually.